Overview

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Status:
Completed
Trial end date:
2018-06-25
Target enrollment:
Participant gender:
Summary
This initial Phase I study will evaluate the dose-related safety and tolerability pharmacokinetics (PK) of CORT125281, and CORT125324 (active metabolite), and pharmacodynamics (PD) after single and multiple ascending oral doses of CORT125281 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Cortisone
Cortisone acetate
Pioglitazone
Prednisone